cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Jazz Pharmaceuticals Plc
20 own
19 watching
Current Price
$155.64
$-0.76
(-0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
9,788.2M
52-Week High
52-Week High
169.98
52-Week Low
52-Week Low
125.36
Average Volume
Average Volume
0.4M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
199.9066
iconMarket Capitalization9,788.2M
icon52-Week High169.98
icon52-Week Low125.36
iconAverage Volume0.4M
iconDividend Yield--
iconP/E Ratio199.9066
What does the Jazz Pharmaceuticals Plc do?
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinson's disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Read More
How much money does Jazz Pharmaceuticals Plc make?
News & Events about Jazz Pharmaceuticals Plc.
PR Newswire
17days ago
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating...
PR Newswire
1month ago
Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN, Jan. 3, 2023 DUBLIN, Jan. 3, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced...
Insider Monkey
1month ago
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2022 Earnings Call Transcript November 9, 2022 Jazz Pharmaceuticals plc beats earnings expectations. Reported EPS is $5.17, expectations were $4.66. Operator: Good day, and thank you for standing by. Welcome to the Q3 2022 Jazz Pharmaceuticals Earnings Call...
GeekWire
1month ago
Zymeworks will receive $350 million from Jazz Pharmaceuticals in return for the right to develop and commercialize Zymeworks lead drug candidate, zanidatamab, in the U.S., Europe and Japan. The new cash builds on a $50 million payment earlier this year and comes after Tuesdays release of positive ...
PR Newswire
1month ago
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab PR Newswire DUBLIN and VANCOUVER, BC, Dec. 21, 2022 Follows positive top-line...
Frequently Asked Questions
Frequently Asked Questions
What is Jazz Pharmaceuticals Plc share price today?
plus_minus_icon
Can Indians buy Jazz Pharmaceuticals Plc shares?
plus_minus_icon
How can I buy Jazz Pharmaceuticals Plc shares from India?
plus_minus_icon
Can Fractional shares of Jazz Pharmaceuticals Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Jazz Pharmaceuticals Plc stocks?
plus_minus_icon
What is today’s traded volume of Jazz Pharmaceuticals Plc?
plus_minus_icon
What is today’s market capitalisation of Jazz Pharmaceuticals Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Jazz Pharmaceuticals Plc?
plus_minus_icon
What percentage is Jazz Pharmaceuticals Plc down from its 52-Week High?
plus_minus_icon
What percentage is Jazz Pharmaceuticals Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$155.64
$-0.76
(-0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$40.92
$-0.28 (-0.68 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$119.00
$-1.25 (-1.04 %)
Catalent, Inc.
Catalent, Inc.
$56.05
$-0.59 (-1.04 %)
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
$45.73
$-1.61 (-3.40 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$40.92
$-0.28 (-0.68 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$119.00
$-1.25 (-1.04 %)
Catalent, Inc.
Catalent, Inc.
$56.05
$-0.59 (-1.04 %)
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
$45.73
$-1.61 (-3.40 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00